Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05736458 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

Network Control TMS fMRI

Start date: March 25, 2019
Phase: N/A
Study type: Interventional

This study uses different types of functional magnetic resonance imagining (fMRI) to generate individual transcranial magnetic stimulation (TMS) targets. During the TMS/fMRI imagining sessions, the investigators stimulate a target of either high or low regional controllability during a working memory task to investigate network responses and the impact of TMS on behavior.

NCT ID: NCT05733390 Terminated - Clinical trials for Autism Spectrum Disorder

A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

Behavior dysregulation is commonly associated with people with autism spectrum disorder (ASD). Irritability is a major safety concern in adults with ASD. This study will assess the efficacy and safety of JZP541 in the treatment of adults with irritability associated with ASD.

NCT ID: NCT05716295 Terminated - Clinical trials for Advanced or Metastatic Solid Tumors

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

ORCHID-1
Start date: February 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.

NCT ID: NCT05686265 Terminated - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Cerebral Nitrosative/Oxidative Stress in Aneurysmal Subarachnoid Haemorrhage

NOX2
Start date: May 11, 2023
Phase:
Study type: Observational

Aneurysmal subarachnoid haemorrhage (SAH) carries a high morbidity and mortality, which is in part due to the development of secondary brain injury. The mechanisms behind this remain incompletely understood, but oxidative/nitrosative stress and disturbances in vasoregulatory mechanisms are believed to be involved. The present study aims to characterise the transcerebral exchange of oxidative/nitrosative stress markers and nitric oxide metabolites during the early phase after SAH compared to healthy volunteers, including the influence of induced changes in arteriel oxygen tension.

NCT ID: NCT05673109 Terminated - Clinical trials for Metastatic Castration Resistant Prostate Cancer

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Start date: February 22, 2023
Phase: Phase 1
Study type: Interventional

This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy. The main goals of this study are to: Evaluate the safety and tolerability of AC176, evaluate pharmacokinetics and preliminary antitumor activity of AC176

NCT ID: NCT05647798 Terminated - Pregnancy Clinical Trials

Intrapartum Glycemic Control in GDMA2

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

This is a randomized, parallel, controlled, non-inferiority trial to assess the impact of a tight versus a more liberalized intrapartum glycemic control in gestational diabetic mothers on neonatal glycemia. National guidelines for the management of intrapartum glucose in women with GDM are lacking. This is likely due to the scarcity of high-quality data on the topic.

NCT ID: NCT05629767 Terminated - Dyslipidemias Clinical Trials

Tracking of Lipid Lowering Therapy in Jordan

JoLLA
Start date: December 11, 2022
Phase:
Study type: Observational [Patient Registry]

The present study aims to examine the clinical practice of modifying the dose of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD), who have LDL-C > 70 mg/dl despite statin treatment.

NCT ID: NCT05625386 Terminated - Clinical trials for Transcranial Magnetic Stimulation

Dual-target, High-dose TMS for PD Patients With FOG

Start date: December 22, 2022
Phase: N/A
Study type: Interventional

The aim of the current study was to verify whether high-dose TMS treatment of the motor and cognitive cortices is more effective in alleviating FOG than conventional-dose TMS of the motor cortex only. Specifically, investigator hypothesized that the effect of dual-target TMS on FOG is better than traditional stimulation of the motor cortex only, and the effect of high-dose TMS is better than conventional doses.

NCT ID: NCT05611086 Terminated - Clinical trials for Lymphoblastic Leukemia, Acute, Childhood

N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia

Start date: August 29, 2019
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to analyze the effect of N-Acetylcysteine administration towards blood oxidant level, transaminase enzyme, and bilirubin level in ALL children who undergo induction phase of chemotherapy. The main question it aims to answer is whether N-Acetylcysteine can decrease oxidative stress level and reduce hepatotoxicity complication. Participants will be evaluated for MDA level, transaminase enzymes and bilirubin level before, during, and after the chemotherapy. Participants will be given capsules containing 600mg of N-Acetylcysteine as adjunctive treatment during the 6 weeks induction phase of chemotherapy. Researchers will compare the lab results to the placebo group to see if there is any significant difference in the results.

NCT ID: NCT05562011 Terminated - Clinical trials for Perioperative/Postoperative Complications

Feasibility of a New Ambulatory Multi-vital Signs Monitor

Start date: August 18, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is evaluate vital signs (VS), which include non-invasive blood pressure, pulse rate, respiratory rate and Oxygen Saturation (SpO2) using a portable wrist monitoring device called a Caretaker. This device has been cleared by the Food and Drug Administration (FDA) for use and allows the study team to check vital signs in a participant's normal setting. Participation in this study will involve wearing this portable device at 2 different time points: 1. for up to 24 hours immediately during and after the participant's preoperative visit to obtain baseline vital signs during normal activity and during sleep and 2. after surgery up to 24 hours while participant recovers prior to discharge from the hospital